Synaptogenix, Nemours Strike Deal on Bryostatin-1 Trial

Synaptogenix, Nemours Strike Deal on Bryostatin-1 Trial

302107

Synaptogenix, Nemours Strike Deal on Bryostatin-1 Trial

Synaptogenix and Nemours A.I. DuPont Hospital for Children have signed an agreement to collaborate on a clinical trial to test the investigational medication bryostatin-1 in people with fragile X syndrome (FXS). “We are excited to participate in a potentially breakthrough therapeutic drug strategy to address this huge unmet medical need,” Mary M. Lee, MD, said in a press release. Lee is chief scientific officer and executive vice president for Nemours Children’s Health System, and physician-in-chief…

You must be logged in to read/download the full post.